Product Description
Nangibotide is Inotrem’s lead compound. It is a synthetic peptide and first-in-class TREM-1 inhibitor. Nangibotide blocks the TREM-1-mediated immune dysregulations in sterile or infectious acute inflammatory syndromes. Nangibotide restores a balanced inflammatory response and improves outcomes, particularly in those patients with high levels of TREM-1 pathway activation. (Sourced from: https://www.inotrem.com/nangibotide-and-monoclonal-antibodies/)
Mechanisms of Action: TREM1 Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inotrem
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Denmark, Finland, France, Ireland, Spain
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Shock, Septic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ASTONISH | P2 |
Active, not recruiting |
Shock, Septic |
2022-05-09 |
24% |